Seminars in Hematology

Papers
(The TQCC of Seminars in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial78
CAR T-cell therapy comes of age: Introductory editorial for the special issue57
Clinical applications of circulating tumor DNA in Hodgkin lymphoma52
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia50
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation49
How to set up a clinical research center in Brazil, as an example of a middle-income country41
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies41
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-1925
Epidemiology and etiology of diffuse large B-cell lymphoma24
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services21
Lessons learned from the Eµ-TCL1 mouse model of CLL21
TET2 mutation as prototypic clonal hematopoiesis lesion20
Somatic mutations in “benign” blood diseases19
Antibody and immunotherapy in diffuse large B-cell lymphoma18
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence17
The role of viruses in HIV-associated lymphomas17
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future15
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?14
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors14
Vaccinations in patients with chronic lymphocytic leukemia14
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics13
The molecular map of CLL and Richter's syndrome13
Clonal hematopoiesis13
outside front cover, PMS 8883 metallic AND 4/C12
Tribute to an editor: Neal S. Young As a Medical Editor and Writer12
Cellular and immunotherapies for myelodysplastic syndromes12
outside front cover, PMS 8883 metallic AND 4/C12
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients11
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations11
outside front cover, PMS 8883 metallic AND 4/C11
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead10
Aplastic anemia: Quo vadis?9
Challenges and opportunities of CAR T-cell therapies for CLL9
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia9
The biology of classical Hodgkin lymphoma9
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)8
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy8
Somatic compensation of inherited bone marrow failure8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS8
Understanding MDS stem cells: Advances and limitations8
The pediatric approach to Hodgkin lymphoma8
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana8
Menin inhibition for the treatment of acute leukemia8
Somatic mutations in acquired pure red cell aplasia8
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials7
The crossroads of cancer therapies and clonal hematopoiesis7
DLBCL arising from indolent lymphomas: How are they different?7
0.087963819503784